Safety issues with bisphosphonate therapy for osteoporosis.

Area of Science:

• Pharmacology
• Bone Metabolism
• Clinical Therapeutics

Background:

• Bisphosphonates (BP) are widely used to improve bone mineral density (BMD) and reduce fracture risk.
• Post-marketing surveillance has revealed safety concerns not evident in initial clinical trials.
• Long-term clinical experience necessitates a re-evaluation of BP safety profiles.

Purpose of the Study:

• To review the established efficacy of bisphosphonates (BP).
• To discuss emerging safety concerns associated with bisphosphonate therapy.
• To provide evidence-based recommendations for long-term bisphosphonate management.

Main Methods:

• Review of randomized controlled trials (RCTs) on bisphosphonate efficacy.
• Analysis of post-marketing surveillance data for safety issues.
• Synthesis of clinical experience regarding bisphosphonate use in osteoporosis and oncology.

Main Results:

• Bisphosphonates (BP) demonstrate efficacy in improving BMD and reducing fracture risk.
• Long-term BP use may be associated with a small increased risk of atypical femoral fracture.
• Osteonecrosis of the jaw is rare with osteoporosis dosing, more common with high-dose i.v. BP in oncology.
• Risks of atrial fibrillation and oesophageal cancer are negligible or not definitively linked to BP.

Conclusions:

• A drug holiday after 5 years of BP treatment should be considered for low-risk patients.
• BP should be avoided in severe renal impairment, pregnancy, and lactation due to limited data.
• Further research is needed to establish long-term safety (>5 years) and guide clinical management.